Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E

Table 4 Characteristics that are statistically different between patients with high serum TNC and high serum IgE levels and others

	High TNC > 37.16	Low TNC < 37.16	High TNC > 37.16	Low TNC < 37.16	P value for multigroup analysis^†	Groups B, C and D	P value between groups A and E^‡
	High IgE > 100	High IgE > 100	Low IgE < 100	Low IgE < 100		Groups B, C and D
	A (n = 36)	B (n = 42)	C (n = 16)	D (n = 32)		E (n = 90)
GINA step 4 + 5, n (%)	29 (80.6)	18 (42.9)	13 (81.3)	21 (65.6)	0.002*	52 (57.8)	0.023*
Peripheral neutrophils (cells/μL)	4593.71 ± 1656.42	3823.77 ± 1249.02	3832.20 ± 1117.89	3735.33 ± 1637.25	0.018*	3793.82 ± 1365.61	0.002*
Peripheral eosinophils (cells/μL)	338.37 ± 302.52	287.01 ± 206.42	214.70 ± 194.18	172.96 ± 172.63	0.027*	233.60 ± 197.73	0.170
Serum IgE (IU/mL)	1120.92 ± 2424.39	831.76 ± 1733.44	46.26 ± 28.61	51.09 ± 25.59	< 0.001*	414.55 ± 1240.42	< 0.001*
Th2-high, n (%)	23 (63.9)	30 (71.4)	0 (0.0)	0 (0.0)	< 0.001*	30 (33.3)	0.003*
Serum TNC (ng/mL)	63.77 ± 29.77	26.04 ± 8.42	53.79 ± 12.95	22.65 ± 7.29	< 0.001*	29.77 ± 14.42	< 0.001*
%FVC (predicted, %)	97.08 ± 12.80	105.44 ± 16.51	107.59 ± 16.01	104.40 ± 18.16	NS	105.45 ± 16.88	0.005*
%FEV₁ (predicted, %)	82.77 ± 15.57	94.92 ± 16.70	95.69 ± 19.99	92.69 ± 20.27	0.005*	94.26 ± 18.45	< 0.001*
%PEF (predicted, %)	96.95 ± 19.02	103.93 ± 19.00	107.31 ± 24.44	107.53 ± 23.42	0.124	105.81 ± 21.48	0.033*
%MMF (predicted, %)	48.56 ± 20.87	63.05 ± 24.47	63.56 ± 32.29	62.88 ± 32.92	0.083	63.08 ± 28.79	0.010*

Data are presented as the mean ± standard deviation unless otherwise indicated
ACT asthma control test, AERD aspirin-exacerbated respiratory disease, BMI body mass index, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GINA Global Initiative for Asthma, ICS inhaled corticosteroid, IgE immunoglobulin E, MMF mid-maximal flow rate, OCS oral corticosteroids, PEF peak expiratory flow, PSL prednisolone, Th2 T-helper cell type 2, TNC tenascin-C, NS not significant
*P < 0.05
†Multigroup analysis performed by Chi square test, One-way ANOVA and Kruskal–Wallis test as appropriate
‡Comparisons performed by Student’s t test, the Mann–Whitney U test, and Fisher’s exact test as appropriate

ISSN: 1710-1492